# Spruce Street Capital LP 13F holdings Q2 2026: $510 million

Spruce Street Capital LP reported $510 million in 13F securities across 30 positions for the quarter ended June 30, 2026, in a holdings report filed August 13, 2026. Its largest holding was Kiniksa Pharmaceuticals Intl at $58.7 million, 11.5% of the reported value. Since Q1 2026 it opened 5 new positions and exited 3.

SpecStream is the live web data engine for teams and agents. It reads the SEC's Form 13F data sets each quarter, and this page is that reading, keyed on the manager's CIK and the security's CUSIP. Ask for the managers or the holdings you track, and each new 13F filing arrives in your sheet, CRM, Slack or agent as the SEC publishes it.

- Quarter: Q2 2026, the quarter ended June 30, 2026
- Reported value: $509,681,144
- Positions: 30
- Filed: August 13, 2026
- Report type: 13F holdings report
- CIK: 2050194
- Form 13F file number: 028-26325
- CRD number: 333213
- Business address: 777 Third Avenue Suite 1704, New York, NY 10017
- SEC filing: [0002050194-26-000005](https://www.sec.gov/Archives/edgar/data/2050194/000205019426000005/0002050194-26-000005-index.htm)
- Investment adviser record: [Form ADV on SpecStream](https://specstream.ai/data/investment-advisers/firm/spruce-street-capital-lp-333213)

## Top 25 holdings by value

The largest of 30 positions by reported value at the end of the quarter ended June 30, 2026. Put and call options are marked in the class. Change is in shares or principal against the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value | Change since Q1 2026 |
| --- | --- | --- | --- | --- |
| [Kiniksa Pharmaceuticals Intl](https://specstream.ai/data/institutional-holders/kiniksa-pharmaceuticals-intl-g52694109) | ORD SHS CL A | 918,070 | $58.7 million | +157,007 |
| [Relay Therapeutics Inc](https://specstream.ai/data/institutional-holders/relay-therapeutics-inc-75943r102) | COM | 2,984,125 | $55.8 million | No change |
| [LB Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/lb-pharmaceuticals-inc-50180m108) | COM SHS | 1,376,159 | $44.7 million | No change |
| [Relmada Therapeutics Inc](https://specstream.ai/data/institutional-holders/relmada-therapeutics-inc-75955j402) | COM | 6,391,328 | $44.2 million | +129,214 |
| [Alto Neuroscience Inc](https://specstream.ai/data/institutional-holders/alto-neuroscience-inc-02157q109) | COM SHS | 1,353,047 | $35.7 million | +27,837 |
| [Dianthus Therapeutics Inc](https://specstream.ai/data/institutional-holders/dianthus-therapeutics-inc-252828108) | COM | 354,816 | $34.6 million | -18,458 |
| [Alkermes PLC](https://specstream.ai/data/institutional-holders/alkermes-plc-g01767105) | SHS | 543,876 | $28.5 million | +225,884 |
| [Savara Inc](https://specstream.ai/data/institutional-holders/savara-inc-805111101) | COM | 3,452,576 | $21.3 million | +69,401 |
| [Vaxcyte Inc](https://specstream.ai/data/institutional-holders/vaxcyte-inc-92243g108) | COM | 306,047 | $17.8 million | +60,338 |
| [Enliven Therapeutics Inc](https://specstream.ai/data/institutional-holders/enliven-therapeutics-inc-29337e102) | COM | 329,006 | $16.7 million | No change |
| [Enanta Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/enanta-pharmaceuticals-inc-29251m106) | COM | 1,088,731 | $15.9 million | +156,133 |
| [Perspective Therapeutics Inc](https://specstream.ai/data/institutional-holders/perspective-therapeutics-inc-46489v302) | COM NEW | 3,693,931 | $12.6 million | +1,066,824 |
| [Inflarx NV](https://specstream.ai/data/institutional-holders/inflarx-nv-n44821101) | COM | 5,352,198 | $12 million | New |
| [Surrozen Inc](https://specstream.ai/data/institutional-holders/surrozen-inc-86889p208) | COM NEW | 432,040 | $11.2 million | No change |
| [Alumis Inc](https://specstream.ai/data/institutional-holders/alumis-inc-022307102) | COM | 392,574 | $11 million | No change |
| [Century Therapeutics Inc](https://specstream.ai/data/institutional-holders/century-therapeutics-inc-15673t100) | COM | 4,059,054 | $9.9 million | No change |
| [Minerva Neurosciences Inc](https://specstream.ai/data/institutional-holders/minerva-neurosciences-inc-603380205) | COM NEW | 1,655,500 | $9.2 million | No change |
| [Sab Biotherapeutics Inc](https://specstream.ai/data/institutional-holders/sab-biotherapeutics-inc-78397t202) | COM NEW | 2,198,502 | $8.6 million | No change |
| [An2 Therapeutics Inc](https://specstream.ai/data/institutional-holders/an2-therapeutics-inc-037326105) | COM | 1,661,073 | $8 million | No change |
| [Erasca Inc](https://specstream.ai/data/institutional-holders/erasca-inc-29479a108) | COM | 422,543 | $7.7 million | No change |
| [Inhibikase Therapeutics Inc](https://specstream.ai/data/institutional-holders/inhibikase-therapeutics-inc-45719w205) | COM NEW | 3,581,603 | $7.3 million | No change |
| [Research Alliance Corp III](https://specstream.ai/data/institutional-holders/research-alliance-corp-iii-g75226103) | ORD SHS CL A | 500,000 | $5.4 million | New |
| [Helix Acquisition Corp III](https://specstream.ai/data/institutional-holders/helix-acquisition-corp-iii-g4444s107) | USD CL A ORD SHS | 500,000 | $5.3 million | No change |
| [Zai Lab LTD](https://specstream.ai/data/institutional-holders/zai-lab-ltd-98887q104) | ADR | 279,110 | $5.3 million | New |
| [Achieve Life Science Inc](https://specstream.ai/data/institutional-holders/achieve-life-science-inc-004468500) | COM | 736,637 | $4.8 million | New |

## New positions in Q2 2026

5 positions not in the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| [Inflarx NV](https://specstream.ai/data/institutional-holders/inflarx-nv-n44821101) | COM | 5,352,198 | $12 million |
| [Research Alliance Corp III](https://specstream.ai/data/institutional-holders/research-alliance-corp-iii-g75226103) | ORD SHS CL A | 500,000 | $5.4 million |
| [Zai Lab LTD](https://specstream.ai/data/institutional-holders/zai-lab-ltd-98887q104) | ADR | 279,110 | $5.3 million |
| [Achieve Life Science Inc](https://specstream.ai/data/institutional-holders/achieve-life-science-inc-004468500) | COM | 736,637 | $4.8 million |
| [Jatt II Acquisition Corp](https://specstream.ai/data/institutional-holders/jatt-ii-acquisition-corp-g50765109) | ORD SHS | 160,000 | $1.8 million |

## Positions exited in Q2 2026

3 positions in the filing for the quarter ended March 31, 2026 and not in this one, with the shares and value reported then.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| Centessa Pharmaceuticals PLC | SPONSORED ADS | 489,849 | $19.5 million |
| Kalvista Pharmaceuticals Inc | COM | 897,681 | $18.1 million |
| [Maze Therapeutics Inc](https://specstream.ai/data/institutional-holders/maze-therapeutics-inc-578784100) | COM | 200,000 | $6 million |

## Also on SpecStream

- [Spruce Street Capital LP Form 13F filing on EDGAR](https://www.sec.gov/Archives/edgar/data/2050194/000205019426000005/0002050194-26-000005-index.htm)
- [Spruce Street Capital LP investment adviser record (Form ADV)](https://specstream.ai/data/investment-advisers/firm/spruce-street-capital-lp-333213)
- [Largest 13F filers in New York](https://specstream.ai/data/institutional-holdings/state/new-york)
- [Largest institutional managers by 13F value](https://specstream.ai/data/institutional-holdings)
- [Most widely held securities in 13F filings](https://specstream.ai/data/institutional-holders)

Source: [the SEC's Form 13F data sets](https://www.sec.gov/data-research/sec-markets-data/form-13f-data-sets). Public data published by the US Securities and Exchange Commission (US government work). Managers report these holdings themselves in Form 13F, and the SEC does not check or guarantee them. Form 13F lists long positions in US listed equities, some options and convertible notes held at the end of the quarter, and leaves out short positions, cash, most bonds and holdings below the reporting threshold. Values are market values in US dollars as the manager filed them. A manager can ask the SEC to keep some positions confidential for a time. This page uses SEC data and is not endorsed or certified by the SEC.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in New York, New York

- [Private equity firms in New York, New York](https://specstream.ai/data/businesses/private-equity-firms/new-york-new-york-united-states)
- [Executive search firms in New York, New York](https://specstream.ai/data/businesses/executive-search-firms/new-york-new-york-united-states)
- [Vocational and technical schools in New York, New York](https://specstream.ai/data/businesses/vocational-and-technical-schools/new-york-new-york-united-states)
- [Media agencies in New York, New York](https://specstream.ai/data/businesses/media-agencies/new-york-new-york-united-states)
- [Colleges and universities in New York, New York](https://specstream.ai/data/businesses/colleges-and-universities/new-york-new-york-united-states)
- [Restaurants in New York, New York](https://specstream.ai/data/businesses/restaurants/new-york-new-york-united-states)
